Human Biome Institute

Silver Sponsor

Human Biome S.A. (HBI) is a private company focused on developing cutting-edge Microbiome-Based Therapeutics. 

BRIEFLY:

‘Second-generation’ microbiome company developing world’s first biosynthetic, donor-independent, autonomous, bio-mimicking microbiome biotherapeutics predicted and synthesized in a deep-tech approach. New drug type, new therapeutic areas, enormous market.

WATCH WHAT WE DO IN THIS 2 mins VIDEO: https://www.youtube.com/watch?v=amP-m7lNqNA

DETAILED:

We are a 'second-generation' microbiome company developing the world's first synthetic, donor-independent autonomous microbiome biotherapeutic (called New-Generation Biotherapeutics; NGBs).
Human Biome (HBi) is developing autonomous microbiome biotherapeutics restoring the full microbiota ecosystem (the most desired feature on the market now, as only restoring the complexity of immunological and ecological networks will provide a full range of interactions with the host and ensure homeostasis). It can be considered a ‘second generation’ microbiome therapeutics company; its innovation is centered on creating strain-dependence-phenomenon-preserving microbiome drugs using its data science-enabled proprietary (deep-tech) Drug Discovery Platform (MicroDrug). The Company is developing the world's first biosynthetic, biomimicking, donor-independent autonomous microbiome biotherapeutic that will have additional targeted and clinically-relevant biological properties identified using artificial intelligence techniques. Commercially – the first biosynthetic, full-microbiota-restoration drug allows to scale the production and reach enormously big markets. AI-driven “intelligent” drug’s features will cure diseases with precision.
We educate the market and create a new market with capitalization in the tens of billions of dollars. Prevention is better than cure. And if treatment is needed, it must be precise and tailored.

HBi’s infrastructure includes a clinical platform for Superdonor-derived, fully anaerobic fecal microbiota transplantation (FMT) studies, a biobank with extensive sample collections (20 000 to date), an AI-driven computational platform to predict effective microbiota components, and a genomics-culturomics ultra-deep tech platform for synthesizing the biotherapeutic. This integrated and unique approach ensures that its drugs are composed of precisely chosen microbiota strains, isolated from donors used in proof-of-concept studies, rather than random healthy people. This is a main advantage of HBi’s concept and platform– to preserve strain-dependence-phenomenon. The biosynthetic form of the drug, self-reproducible in bioreactors, offers unlimited possibilities for targeting diseases in which the microbiome plays a role, without the risks of donor dependency.

As a truly deep-tech approach, our technology and drug concept go beyond today's standards. We are creating a new category of medicine and a new type of therapy formula, developed over 10 years of work on the microbiome, antibiotic resistance, bone marrow transplantation and immunology fields. By combining all these areas, we have developed a technology and treatment concept that has the potential to change the paradigms of prevention and treatment in the current biggest unmet clinical needs (antibiotic resistance, immunooncology, transplant immunology and longevity/wellbeing). Our NGBs will be a sequential therapy that rebuilds the microbiome and intestinal ecosystem, provides proper immune stimulation, and restores well-being, not just curing the disease.In the fields of antibiotic resistance, transplant immunology, immunotherapy, and cancer, we are among the world's pioneers in using the microbiome as a treatment/preventive method.

Company is seeking co-investors for Series A (and eventually B) round and early-partnering with Pharma Companies or Others for our pipeline’s products.

Our biosynthetic, donor-independent microbiome drugs pipeline includes 4 therapies:
1.     ARB NGB – to decolonize Antibiotic-Resistant Bacteria and prevent invasive drug-resistant infections, Enormous market with over 800 mln people colonized with clinically relevant antibiotic-resistant bacteria (anti-infectives only $18.3B)
2.     Immunobooster NGB -  to enhance an immune response to anticancer therapies and prevent immune complications of transplant procedures (bone marrow, solid organs)
3.     Longevity NGB – to optimize the gut microbiome to achieve longevity and wellbeing
4.    CDI NGB – to prevent recurrence of C.difficile Infection and restore microbiome ecosystem

All drugs have their own clinical programs and are being developed in our deep-tech Drug Discovery Platform ensuring their precision and tailored mode of action.

website